David Beckham’s IM8 longevity supplement brand secures US$1B in funding

Prenetics Global, parent of David Beckham’s co-founded longevity supplement IM8, has closed US$1 billion in growth financing from General Catalyst’s Customer Value Fund (CVF). Since the label’s NASA research-backed powdered drinks launched in December 2024, it has expanded rapidly in direct-to-consumer supplements — scaling to over US$200 million in revenue. 

CVF will finance up to 70% of IM8’s marketing costs, with IM8 retaining full creative direction. General Catalyst will receive a capped share of income from customer cohorts financed by the deal.

“IM8 is a category-defining consumer health business, and the underlying cohort economics are among the strongest we’ve seen across the Customer Value Fund portfolio,” says Adit Swarup, a partner at General Catalyst and lead on the CVF partnership with Prenetics Global.

“Their cohort retention data is remarkable: highly consistent across geographies, subscription tenors, and product lines, with quarterly renewal rates setting new industry benchmarks for direct-to-consumer health.”

Since its launch, IM8 has reportedly sold over 50 million servings to customers and says it is now delivering approximately 200,000 servings every day across 43 countries. The brand’s partner and equity-partner roster includes public figures David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty, and Inter Miami CF.

Prenetics Global’s financial outlook

Prenetics Global says it is entering this partnership with approximately US$139.7 million in total estimated cash.

IM8’s financing from CVF follows significant strategic moves for Prenetics Global, including its reclassification as a consumer health business from a clinical diagnostics and genomics testing company.

New product launches for IM8 are planned across Q4 2026 and Q1 2027, including IM8 Hydration in Q4 2026 and what the brand teases as a “category-first” premium gummies line in Q1 2027.

IM8 shares that it is continually expanding its clinical evidence base, with two active randomized controlled trials on gut health and longevity currently underway.

According to Innova Market Insights data, 73% of consumers globally consider healthy aging extremely or very important. In its recent report on launches from April 2021 to March 2026, it highlights especially strong growth in longevity-focused biotics, botanical and herbal supplements, as well as gender-specific supplements.

Summer sales lift projections

Currently, IM8 offers two flagship products: Daily Ultimate Essentials, a 90-ingredient daily nutrition foundation, and Daily Ultimate Longevity. To test these products, the company delivered 3D organoids — miniature, simplified versions of human tissues — into outer space to study accelerated aging, leveraging microgravity’s unique environment that speeds up this process.

IM8’s daily drink formulas are developed in collaboration with doctors and scientists from the US Mayo Clinic and the former chief scientist of NASA. While its Daily Ultimate Essentials PRO is based on a 90-ingredient nutritional foundation, its targeted Daily Ultimate Longevity powder features a proprietary, science-backed 5-Complex System that claims to address the biological roots of aging.

David Beckham, co-founder of IM8.The brand highlights its strongest month in company history in June 2026, with preliminary unaudited monthly revenue of approximately US$17 million. The brand says its momentum has continued into the third quarter.

Prenetics Global has raised its full-year 2026 IM8 revenue guidance to US$210–220 million, up from a previous US$190–210 million. This is its second guidance increase this year.

In its second full year of operations, Prenetics Global forecasts IM8 will reach US$300 million in annualized run-rate revenue by year-end 2026, and deliver in excess of US$400 million in full-year 2027 revenue.

IM8’s long-term strategic path aims for a billion-dollar scale in annual revenue over the next few years.

Sales and marketing boost

The brand will deploy the new US$1 billion capital expected across its sales and marketing activities, which include digital performance marketing across every major platform, offline and connected-TV media, ambassador and athlete partnerships, brand activations and sponsorships, content production, and retention marketing.

According to Prenetics Global, IM8’s customer acquisition investments have consistently returned multiples of their cost in gross profit over the customer lifetime.

“Every mature customer cohort since launch has exceeded the performance thresholds General Catalyst diligenced against, cohort after cohort, in the deepest diligence process I’ve been through as a founder. That is what has led us here,” says Danny Yeung, CEO of Prenetics and co-founder of IM8.

“For a year, investors have asked whether we were spending too much on customer acquisition. Now the proof is public: every dollar we have ever spent acquiring customers has already returned US$1.44 in gross profit — and that number rises every month, because these are subscribers,” he continues.

“The right question was never whether we were spending too much; it’s whether we were spending enough. With this financing, we can now accelerate brand and marketing across our 43 countries without issuing a single share to fund it — a structure that keeps every dollar of shareholder value with our shareholders. Our ambition is to build a multi-billion-dollar global consumer health brand. This partnership materially accelerates that path.”

AI-native marketing engine

Behind the scenes, IM8 operates an AI-native marketing engine, across advertising, merchandising, customer experience, and retention. According to the company, this acquisition system runs continuous, automated experimentation “at a scale few consumer companies attempt.”

“Any given time, thousands of ads are live and being tested across 43 markets; every landing page, funnel, and website experience is subject to always-on A/B and multivariate testing; and predictive models score cohort quality and customer lifetime value in near real time, governing where the next dollar of acquisition spend goes — the same transaction-level cohort data General Catalyst underwrote in its diligence,” details IM8.

The brand states that its system compounds in efficiency as data accumulates, and it is the main engine through which the CVF capital will be deployed.

“When you combine IM8’s best-in-class unit economics, a repeatable customer acquisition engine across 43 countries, and a founding team led by Danny Yeung with the cultural reach of a co-founder like David Beckham, you have exactly the kind of business the CVF was built to accelerate,” says Swarup.

After General Catalyst has recovered its investment and capped return on any given monthly cohort, all subsequent value from those customers accrues entirely and permanently to IM8.